12.06.2007 09:54:00
|
Johnson & Johnson Selects ArisGlobal as its Global Pharmacovigilance and Safety Partner
ArisGlobal, the leading provider of pharmacovigilance and safety systems
to the life science industry, today announced its strategic partnership
with Johnson & Johnson (NYSE:JNJ). Johnson & Johnson will deploy the
ArisGlobal Total Safety suite of products on a global basis to replace
its in-house systems.
Johnson & Johnson’s goal was to select a
partner who could supply a single, harmonized platform to provide
global, state of the art safety case management, signal detection and
surveillance capabilities. In addition, Johnson & Johnson needed a
partner with a shared vision and strategy to evolve and develop systems
to meet the current and future demands of a global organization such as
Johnson & Johnson.
Johnson & Johnson selected ArisGlobal as its partner because ArisGlobal
provides the most comprehensive safety solutions on the market today,
but more importantly, shares Johnson & Johnson’s
vision and strategy on the future of drug safety.
"We chose ArisGlobal because they understand
our business environment and demonstrated excellent commitment during
our business and technology requirements sessions. The services and
functionality provided with ARISg combined with our development
partnership with ArisGlobal to enhance ARISg will support our
requirements,” said William Truhe, Vice
President of Informatics, Benefit Risk Management at Johnson & Johnson
Pharmaceutical Research & Development, L.L.C. "With
ArisGlobal’s ARISg robust feature set,
flexible data model ,intuitive user interface and ability to integrate
with our key systems, Johnson & Johnson will incorporate this solution
into our existing enterprise-wide processes, knowing that they have the
ability to perform enhancements at an efficient pace.”.
"The fact that Johnson & Johnson has entrusted ArisGlobal to support
their most critical business needs is extremely satisfying. It is widely
known that Johnson & Johnson has been at the forefront of drug safety
initiatives and our partnership with them will allow us to develop a
solid pharmacovigilance and risk management platform to satisfy the
demands of government, the regulators and the consumer," said Simon
Sparkes, Vice President, Global Sales and Marketing at ArisGlobal.
About ArisGlobal, L.L.C.
ArisGlobal, L.L.C. is a leading provider of Pharmacovigilance and
Safety, Registration Information Management, Clinical Trials Management
and Medical Communications software solutions to the Life Sciences
industry. ArisGlobal’s software solutions are
being used by over 130 life science companies around the world.
ArisGlobal software helps companies meet international regulatory
requirements, manage risk, improve operational efficiencies and easily
share mission-critical information on a global basis.
About Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., is part
of Johnson & Johnson, the world's most broadly based producer of health
care products. Johnson & Johnson Pharmaceutical Research & Development,
L.L.C., is headquartered in Raritan, New Jersey (USA), and has
facilities throughout Europe and the United States. Johnson & Johnson
Pharmaceutical Research & Development, L.L.C., is leveraging drug
discovery and drug development in a variety of therapeutic areas to
address unmet medical needs worldwide.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Johnson & Johnsonmehr Nachrichten
27.11.24 |
Dow Jones 30 Industrial-Titel Johnson Johnson-Aktie: So viel hätte eine Investition in Johnson Johnson von vor 3 Jahren gekostet (finanzen.at) | |
26.11.24 |
Dow Jones aktuell: Dow Jones letztendlich mit Gewinnen (finanzen.at) | |
26.11.24 |
Zuversicht in New York: Dow Jones am Dienstagnachmittag mit Gewinnen (finanzen.at) | |
26.11.24 |
Verluste in New York: Dow Jones verbucht am Mittag Abschläge (finanzen.at) | |
22.11.24 |
Dow Jones-Handel aktuell: Dow Jones zum Ende des Freitagshandels mit Kursplus (finanzen.at) | |
22.11.24 |
Starker Wochentag in New York: Dow Jones verbucht Zuschläge (finanzen.at) | |
22.11.24 |
Börse New York in Grün: Pluszeichen im Dow Jones (finanzen.at) | |
20.11.24 |
Dow Jones 30 Industrial-Wert Johnson Johnson-Aktie: So viel hätten Anleger an einem Johnson Johnson-Investment von vor einem Jahr verdient (finanzen.at) |
Analysen zu Johnson & Johnsonmehr Analysen
Aktien in diesem Artikel
Johnson & Johnson | 147,36 | 0,07% |
Indizes in diesem Artikel
Dow Jones | 44 722,06 | -0,31% | |
S&P 500 | 5 998,74 | -0,38% | |
S&P 100 | 2 883,15 | -0,41% | |
NYSE US 100 | 17 376,20 | -0,02% |